EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

Vanita R Aroda iD, Umut Erhan, Peter Jelnes, Juris J Meier iD, Morten Tind Abildlund, Richard Pratley iD, Tina Vilsbøll iD, Mansoor Husain iD

Diabetes, Obesity and Metabolism · 2023-05 · 25 (5) · 1385-1397

DOI: 10.1111/dom.14990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.02.2023. Verfasst von Vanita R Aroda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Retinopathy, Pancreatitis, Gastrointestinal Diseases. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S, Søborg, Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now available as oral and subcutaneous formulations, and some have indications for reducing cardiovascular risk. The expanded scope for these therapies warrants comprehensive safety evaluations. We report the safety/tolerability of subcutaneous and oral semaglutide from the SUSTAIN and PIONEER clinical trial programmes, respectively. Materials and methods Adverse events (AEs) from 16 randomized placebo‐ or active‐controlled phase IIIa trials in patients with type 2 diabetes (n = 11 159) including once‐weekly subcutaneous semaglutide (n = 3150; SUSTAIN trials) or once‐daily oral semaglutide (n = 4116; PIONEER trials) were analysed. Data pools were analysed for each programme, with separate analyses of cardiovascular outcomes trials (CVOTs; n = 6480).

Results

In the phase IIIa pools, gastrointestinal disorders were reported in 41.9%/39.1% of patients with subcutaneous/oral semaglutide, respectively (most prevalent during initiation/escalation) versus 22.0%/24.8% with comparators. Rates of kidney disorders, acute pancreatitis, malignant neoplasms, hypoglycaemia, diabetic retinopathy, heart failure and other cardiovascular events were similar for semaglutide versus comparators. Cholelithiasis incidence was higher with subcutaneous and oral semaglutide versus placebo. Diabetic retinopathy incidence was higher with subcutaneous semaglutide versus placebo in SUSTAIN 6. Small pulse rate increases occurred with both formulations; there was no increased rate of arrhythmias. Fatal AE incidence was similar between semaglutide and comparators. Versus placebo, CVOTs showed a reduced risk of major adverse cardiovascular events with subcutaneous semaglutide and non‐inferiority criteria were met with oral semaglutide.

Conclusions

The most common AEs with semaglutide were gastrointestinal disorders, which decreased with continued therapy. These comprehensive safety/tolerability data may better inform patient selection and guidance in care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic RetinopathyPancreatitisGastrointestinal DiseasesHumansHypoglycemic AgentsAcute DiseaseGlucagon-Like PeptidesSemaglutide

Stichwörter der Autor:innen

GLP-1antidiabetic drugphase III studyrandomized trialtype 2 diabetes

Substanzen

Hypoglycemic AgentsGlucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Department of Internal Medicine, Gastroenterology, Hepatology and Diabetology, Augusta Clinic, Bochum, Germany.
  • AdventHealth Translational Research Institute, Orlando, Florida, USA.
  • Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Vanita R Aroda, Juris J Meier, Richard Pratley, Tina Vilsbøll, Mansoor Husain

Förderung

  • Novo Nordisk A/S, Søborg, Denmark

Zitieren

APA

Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Abildlund, M. T., Pratley, R., Vilsbøll, T., & Husain, M. (2023). Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, Obesity and Metabolism, 25(5), 1385-1397. https://doi.org/10.1111/dom.14990

Vancouver

Aroda VR, Erhan U, Jelnes P, Meier JJ, Abildlund MT, Pratley R, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, Obesity and Metabolism. 2023;25(5):1385-1397. doi:10.1111/dom.14990

BibTeX
@article{Aroda2023,
  author = {Aroda, Vanita R and Erhan, Umut and Jelnes, Peter and Meier, Juris J and Abildlund, Morten Tind and Pratley, Richard and Vilsbøll, Tina and Husain, Mansoor},
  title = {Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {5},
  pages = {1385--1397},
  doi = {10.1111/dom.14990}
}
Kostenlos starten →